- Conditions
- Sudden Cardiac Death, Prolonged QTc Interval
- Interventions
- EC with nicotine, EC without nicotine, control, TC with nicotine (own brand), research TC with very low level nicotine
- Other
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 21 Years to 45 Years
- Enrollment
- 110 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Los Angeles, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–5
of 5
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Prolonged QTc Interval, Pharmacokinetic
- Interventions
- 100 μg cebranopadol, 200 μg cebranopadol, 400 μg cebranopadol, Placebo to cebranopadol encapsulated tablets, 400 mg Moxifloxacin, Placebo to moxifloxacin encapsulated tablets
- Drug
- Lead sponsor
- Tris Pharma, Inc.
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 171 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- West Bend, Wisconsin
- Conditions
- Prolonged QTc Interval
- Interventions
- Deferiprone, deferiprone matching placebo tablets, moxifloxacin, placebo
- Drug
- Lead sponsor
- ApoPharma
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Prolonged QTc Interval
- Interventions
- Estetrol 20 mg, Estetrol 100 mg, Placebo, Moxifloxacin 400 mg
- Drug
- Lead sponsor
- Estetra
- Industry
- Eligibility
- 40 Years to 65 Years · Female only
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Atrial Fibrillation New Onset, Hemorrhage, Prolonged QTc Interval, Ventricular Tachycardia, Medical Care; Complications, Late Effect of Complications
- Interventions
- Ranolazine, Placebo
- Drug
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Staten Island, New York